Encapsulation of cardiac stem cells in superoxide dismutase-loaded alginate prevents doxorubicin-mediated toxicity

Journal of Tissue Engineering and Regenerative Medicine

Volumn 7, Issue 4, 2013, Pages 302-311

  Liu, Ting Chu Ken ^a   Ismail, Siti ^a,b   Brennan, Orlaith ^a,b   Hastings, Conn ^a,b   Duffy, Garry P ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cardiac stem cells; Chemotherapy; Doxorubicin; Heart failure; Pro survival; Superoxide dismutase

Indexed keywords

ALGINATE; CARDIOLOGY; CELL CULTURE; CELL DEATH; ENCAPSULATION; ENZYMES; HEART; HYDROGELS; METABOLISM; OXYGEN; STEM CELLS;

ANTHRACYCLINES; CARDIAC STEM CELLS; CARDIOTOXICITY; CELL SURVIVAL; DOXORUBICIN; HEART FAILURE; PRO-SURVIVAL; REACTIVE OXYGEN SPECIES; SUPER OXIDE DISMUTASE; SUPEROXIDE DISMUTASES;

CHEMOTHERAPY;

ALGINIC ACID; DOXORUBICIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL COUNT; CELL CULTURE; CELL ENCAPSULATION; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG FORMULATION; HEART PROTECTION; HYDROGEL; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT;

EID: 84875809439     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.523     Document Type: Article

References (35)

1. Anversa P, Kajstura J, Leri A, et al. 2006; Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 113: 1451-1463.
2. Bearzi C, Rota M, Hosoda T, et al. 2007; Human cardiac stem cells. Proc Natl Acad Sci USA 104: 14068-14073.
3. Calafiore R, Basta G, Luca G, et al. 2006; Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transpl Proc 38: 1156-1157.
4. Champe PC, Harvey RA, Ferrier DR. 2008; Pentose phosphate pathway and NADPH. In Biochemistry, Stryer L (ed.). Lippincott Williams and Wilkins: Baltimore, MD; 148.
5. Chatterjee K, Zhang J, Honbo N, et al. 2010; Doxorubicin cardiomyopathy. Cardiology 115(2): 115-162.
6. Curran CF, Narang PK, Reynolds RD. 1991; Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev 18: 241-252.
7. Davis DR, Zhang Y, Smith RR, et al. 2009; Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One 4: e7195.
8. De Angelis A, Piegari E, Cappetta D, et al. 2010; Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121: 276-292.
9. De Vos P, Marchetti P. 2002; Encapsulation of pancreatic islets for transplantation in diabetes: the untouchable islets. Trends Mol Med 8: 863-866.
10. Ewer MS, Ewer SM. 2010; Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7(10): 564-575.
11. Ferreira-Martins J, Rondon-Clavo C, Tugal D, et al. 2009; Spontaneous calcium oscillations regulate human cardiac progenitor cell growth. Circulation Res 105: 764-774.
12. Gonzalez CA, Rota M, Nurzynska D, et al. 2008; Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. Circulation Res 102: 597-606.
13. Gopinath S, Vanamala SK, Gondi CS, et al. 2010; Human umbilical cord blood derived stem cells repair doxorubicin-induced pathological cardiac hypertrophy in mice. Biochem Biophys Res Commun 395: 367-372.
14. Hallewell RA, Laria I, Tabrizi A, et al. 1989; Genetically engineered polymers of human CuZn superoxide dismutase. Biochemistry and serum half-lives. J Biol Chem 264: 5260-5268.
15. Johnson F, Giulivi C. 2005; Superoxide dismutases and their impact upon human health. Mol Aspects Med 26: 340-352.
16. Kalyanaraman B, Joseph J, Kalivendi S, et al. 2002; Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
17. Kizilel S, Garfinkel M, Opara E. 2005; The bioartificial pancreas: progress and challenges. Diabetes Technol Therap 7: 968-985.
18. Lefrak EA, Pitha J, Rosenheim S, et al. 1973; A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32: 302-314.
19. Li TS, Takahashi M, Ohshima M, et al. 2008; Myocardial repair achieved by the intramyocardial implantation of adult cardiomyocytes in combination with bone marrow cells. Cell Transpl 17: 695-703.
20. Lim F, Sun AM. 1980; Microencapsulated islets as bioartificial endocrine pancreas. Science 210: 908-910.
21. Luthy A, Furrer M, Waser M. 1992; Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. J Heart Lung Transpl 11: 815-816.
22. Ogino T, Inoue M, Ando Y, et al. 1988; Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. Int J Protein Peptide Res 32: 153-159.
23. Outomuro D, Grana DR, Azzato F, et al. 2007; Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol 117: 6-15.
24. Paulides M, Kremers A, Stohr W, et al. 2006; Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediat Blood Cancer 46: 489-495.
25. Pouillart P. 2004; Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treatm Rev 30: 643-650.
26. Regnault C, Soursac M, Roch-Arveiller M, et al. 1996; Pharmacokinetics of superoxide dismutase in rats after oral administration. Biopharmaceut Drug Disposition 17: 165-174.
27. Seifert CF, Nesser ME, Thompson DF. 1994; Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28: 1063-1072.
28. Seshadri G, Sy JC, Brown M, et al. 2010; The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury. Biomaterials 31: 1372-1379.
29. Smith RR, Barile L, Cho HC, et al. 2007; Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115: 896-908.
30. Soon-Shiong P. 1999; Treatment of type I diabetes using encapsulated islets. Adv Drug Deliv Rev 35: 259-270.
31. Sriskandan S, O'Brien MER, Smith IE, et al. 1994; Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. Postgrad Med J 70: 759-761.
32. Takemura G, Fujiwara H. 2007; Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Progress Cardiovasc Dis 49: 330-352.
33. Takka S, Gurel A. 2010; Evaluation of chitosan/alginate beads using experimental design: formulation and in vitro characterization. AAPS PharmSciTech 11: 460-466.
34. Thomas I, Caborn S, Manara AR. 2008; Experiences in the development of non-heart beating organ donation scheme in a regional neurosciences intensive care unit. Br J Anaesth 100: 820-826.
35. van Dalen EC, Caron HN, Dickinson HO, et al. 2008; Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev CD003917.